Acute Kidney Injury Market Report 2026

The acute kidney injury market size has grown strongly in recent years. It will grow from $5.72 billion in 2025 to $6.09 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to limited access to advanced renal care, rising prevalence of comorbidities like diabetes and hypertension, growing hospital infrastructure, adoption of conventional dialysis techniques, increasing awareness of aki complications.

The acute kidney injury market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancement in renal replacement therapies, development of novel nephroprotective drugs, expansion of ambulatory surgical centers, rising use of biomarkers for early detection, integration of ai-based monitoring systems in renal care. Major trends in the forecast period include increasing adoption of dialysis and drug therapies, rising incidence of acute kidney injury globally, growing focus on early diagnosis and biomarker development, expansion of urinary implant applications, integration of minimally invasive techniques in aki management.

Increased prevalence of diabetes is expected to drive the growth of the acute kidney injury market going forward. Diabetes is a group of metabolic disorders characterized by elevated blood sugar levels, either due to insufficient insulin production by the body or because cells do not respond effectively to insulin. The rising prevalence of diabetes is fueled by factors such as growing obesity rates, unhealthy diets, sedentary lifestyles, aging populations, and improved awareness and diagnosis. Acute kidney injury induces metabolic and inflammatory changes that can affect insulin resistance and glucose regulation, highlighting a complex interaction that may influence diabetes progression and management. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increased prevalence of diabetes is fueling growth in the acute kidney injury market.

Major companies operating in the acute kidney injury (AKI) market are concentrating on obtaining regulatory approvals to expand their product portfolios and introduce novel treatment options. Regulatory approvals are official authorizations granted by bodies such as the FDA or EMA, allowing a product to be marketed and sold after meeting safety, efficacy, and quality standards. For instance, in December 2023, Mission Therapeutics Ltd., a UK-based biotechnology company, received FDA approval to commence a Phase II clinical trial for its lead asset, MTX652, targeting acute kidney injury (AKI) in high-risk patients following cardiac surgery. The therapy is designed to target key pathways involved in kidney injury and repair, aiming to reduce inflammation, prevent further kidney damage, and promote recovery. The trial’s distinctive feature is its focus on leveraging novel therapeutic mechanisms to address the molecular causes of AKI, potentially offering more effective treatment options than existing interventions. The Phase II trial will assess MTX652’s safety, efficacy, and pharmacokinetics, providing critical data to support broader clinical adoption and potential regulatory approval.

In October 2024, BioPorto A/S, a Denmark-based in vitro diagnostics company, partnered with Beckman Coulter, Inc., to expand access to its acute kidney injury (AKI) diagnostic solutions. Through this collaboration, Beckman Coulter will distribute BioPorto’s neutrophil gelatinase-associated lipocalin (NGAL) tests across its DxC and AU clinical chemistry analyzers, enabling wider adoption of early AKI detection tools. Beckman Coulter, Inc. is a US-based diagnostics company specializing in early detection solutions for acute kidney injury.

Major companies operating in the acute kidney injury market are Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Asahi Kasei Medical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB.

North America was the largest region in the acute kidney injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute kidney injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acute kidney injury market by increasing costs for imported dialysis machines, urinary implants, and advanced renal monitoring equipment. Segments like dialysis systems and urinary implants are most affected, particularly in regions such as north america, europe, and asia-pacific where imports are significant. This has led to higher treatment costs and potential delays in adoption. On the positive side, tariffs have encouraged local manufacturing, development of domestic alternatives, and investment in regional production capacities.

The acute kidney injury market research report is one of a series of new reports that provides acute kidney injury market statistics, including acute kidney injury industry global market size, regional shares, competitors with a acute kidney injury market share, detailed acute kidney injury market segments, market trends and opportunities, and any further data you may need to thrive in the acute kidney injury industry. This acute kidney injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute kidney injury (AKI) refers to a sudden decline in kidney function, resulting in the buildup of waste products, electrolytes, and fluids in the body. It can develop rapidly over hours or days and is often caused by factors such as reduced blood flow, direct kidney damage, or urinary tract obstruction.

The main types of acute kidney injury are pre-renal kidney injury, post-renal kidney injury, and intrinsic kidney injury. Pre-renal kidney injury occurs when there is a significant reduction in blood flow to the kidneys, leading to decreased filtration. Treatments for AKI include dialysis, drug therapy, and urinary implants, and these are provided to end users such as hospitals, ambulatory surgical centers, and others.

The acute kidney injury market includes revenues earned by entities by providing services such as urinalysis & biomarker testing, imaging services, dialysis services, and surgical & interventional procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.